In MS patients also developing metabolic syndrome, pioglitazone treatment decreases leptin and increases adiponectin serum levels in association with reduced secretion of pro-inflammatory cytokines by PBMC [122]. The gene discussed is LEP; the disease is metabolic syndrome.